The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone and Consolidated Financial Results for the half year ended 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts less than Nifty Microcap 250 and 4.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Trident Lifeline posted strong H1 FY26 results with standalone revenue from operations rising to ₹4,625.86 lacs versus ₹3,039.82 lacs in H1 FY25, a jump of about 52%. Standalone net profit grew roughly 31% to ₹841.71 lacs from ₹640.43 lacs, while consolidated revenue surged around 82% to ₹5,335.68 lacs and consolidated profit after minority interest climbed to ₹801.13 lacs from ₹538.75 lacs, boosted by recently acquired subsidiaries. Quarterly (Q2 FY26) standalone revenue of ₹2,744.03 lacs was up about 75% year-on-year, with Q2 PAT at ₹494.12 lacs. Earnings per share (not annualised) stood at ₹7.26 standalone and ₹6.91 consolidated for the half year. The auditor (A Bafna & Associates) issued an unmodified limited review report, and the company noted nil investor complaints during the period.
Positive for shareholders — robust top-line and bottom-line growth driven by both core operations and subsidiary consolidation, though margin compression and negative operating cash flow in the half year are points worth watching.